IND submission is a major milestone in the life of your drug. We can provide all supporting analytical data to help ensure a smooth application process.
We have the expertise, flexibility, and resources to provide a full range of pharmaceutical API custom development services at every stage of the lifecycle.
We can provide lab-, kilo- and pilot-scale manufacturing for preclinical studies and all phases of clinical trials, supplying milligram to kilogram quantities.
Cambrex brings more than 40 years of generic API manufacturing experience to its pharmaceutical partners. From our sites in Italy, Sweden, and the USA, we are a leading global supplier of generic APIs.
Drug substance tech transfer sounds so simple on the surface, but it’s a complex activity carrying a number of technical, regulatory, and quality risks.
At Cambrex, we provide a range of technologies equipped to solve your API manufacturing challenges, and we are flexible enough to handle the most complex molecules.
If you’re looking to outsource drug product development to a CDMO, you need a collaborative partner who will engage you deeply to understand the unique needs of your project.
From pre-formulation to commercial manufacturing and packaging, you can trust Cambrex to deliver your complex dosage forms with the perfect combination of technology, expertise, and collaboration.
At Cambrex, we offer a tried and trusted approach to technology transfer, for scale-up or when transitioning to a different facility.
We are equipped to take on projects at any size or scale, offering established pediatric formulation and development expertise and to-scale manufacturing capabilities.
Biopharma companies at all stages of development, rely on our expertise and broad capabilities to produce the clinical trial supply of drug products they need, when they need them.
We can support you, at any size or stage, with a range of primary and secondary packaging solutions.
You can rely on our extensive portfolio of analytical development solutions and testing services to rapidly advance your molecule for the greatest chance of success.
Cambrex offers a comprehensive suite of testing services for complex biopharmaceuticals including standalone analytical R&D, method validation, release testing, ICH stability, and routine QC testing.
We’re solid state chemistry experts who can deliver timely, phase-appropriate solutions to optimize the physical stability of your API, develop a more bioavailable formulation or overcome other challenges.
Cambrex’s experienced analysts are well-equipped to ensure microbial testing is of the highest quality for our customers and delivered with a quick and reliable turnaround.
Cambrex and Q1 Scientific’s stability storage and sample management capabilities provide a variety of pharmaceutical storage conditions, with walk-in and reach-in chambers that meet all ICH Q1A requirements.
Cambrex is here to support you in early-phase development. Our development experts apply their ingenuity and skill to address your unique challenges.
Our teams of creative problem-solvers work closely with you to accelerate drug development timelines, optimize processes, and meet regulatory requirements.
We understand that the commercial phase of drug development can be challenging, especially when it comes to manufacturing at scale and meeting changing market demands.
Cambrex is a leading global supplier of more than 70 generic APIs, as well as intermediates and derivatives.
05.24.2011
East Rutherford, NJ and Copenhagen, Denmark – Cambrex Corporation(NYSE: CBM, “Cambrex”) will be exhibiting and presenting at the Biotech Outsourcing Strategies cmc2011 (BOS cmc2011) in Hørsholm, Denmark, near Copenhagen. The one day conference, being held June 16, 2011 at Søhuset Conference Centre, will feature industry experts in small molecule and biopharmaceutical Custom Manufacturing Controls (CMC) development for Pharma, Biotech and Custom Research Organizations (CRO).
Cambrex will be showcasing its contract service capabilities ranging from development to finished dosage form manufacture with a portfolio of offerings that include controlled substances, high potency APIs, high energy chemistries, drug delivery and enzymatic biotransformation technologies. Cambrex manufactures over 120 generic and branded APIs, along with advanced intermediate products.
In the Biologics speaker track, Dr. Dieter Plogmann, Business Development for Cambrex IEP (Wiesbaden, Germany) will present on Biocatalysis R&D, Services and Technologies. His presentation will detail Cambrex IEP’s more than 10 years of experience developing enzyme-catalyzed biotransformations using a toolbox of more than 160 cloned and over-expressed oxidoreductases, as well as providing custom development and R&D screening services.
Cambrex IEP’s biocatalysis technology provides high yields and enantiomeric excess at commercial volumes for the manufacture of chiral amines and alcohols. By utilizing enzymatic processes to produce the desired chiral product, manufacturing and cost-efficiencies are gained versus traditional chemical synthesis. Producing the desired enantiomers in excellent yields and high enantiomeric excess eliminates processing steps including resolution which are a major source of yield loss.